Pharmacological Treatment of Colorectal Cancer
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 15 September 2024 | Viewed by 3884
Special Issue Editor
Interests: cancer cell signaling; targeted therapy of colorectal cancer; anticancer natural products; cancer stem cells; cancer pathology
Special Issue Information
Dear Colleagues,
According to the statistical data of the World Health Organization, colorectal cancer (CRC) was the third most common cancer type and the second most common cause of cancer death worldwide in 2020, and it leads to almost 1 million deaths per year. The treatment strategies of CRC are still a very important medical issue for human health.1,2
The treatment for CRC is divided into two parts: local treatments and systemic treatments. The local treatments for CRC, including surgery, ablation, embolization, and radiation therapy, are useful for earlier-stage cancers without deep invasion or metastasis. However, more than 85 percent of colorectal cancers are found to be advanced, deeply invaded or even metastasized. Systemic treatments using pharmacological strategies including chemotherapy, targeted therapy, and immunotherapy are used in patients with advanced and metastatic colorectal cancer.3 Even though recent advances have improved colorectal cancer survival rates, the effectiveness of treatment and the quality of life of patients still requires more improvement.
In this Special Issue, we invite experts and research teams in this field to propose advanced pharmacological treatment strategies to improve the efficacy of colorectal cancer treatment and improve the quality of life of patients. We welcome original or review articles on discussing novel medications of CRC in targeted therapy, immunotherapy, and anti-angiogenesis agents and their molecular mechanisms, accompanying biomarkers. or pharmacogenomics. Our sincere hope is that through this Special Issue, there will be a breakthrough in the treatment of colorectal cancer.
- https://www.iarc.who.int/cancer-type/colorectal-cancer/
- https://www.wcrf.org/cancer-trends/colorectal-cancer-statistics/
- https://www.cancer.org/cancer/colon-rectal-cancer/treating.html
Dr. Chih-ping Hsu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- chemotherapy
- targeted therapy
- immunotherapy
- quality of life
- molecular marker
- cancer prevention